- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07789184
Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
26 augustus 2026 bijgewerkt door: Hua Huang, MD, PhD
A Prospective, Multicenter, Phase III Randomized Controlled Trial Evaluating the Impact of Radical Surgery Versus Non-Surgery on Prognosis and Quality of Life in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy (ALANO Study, CGCA2603 Study)
The goal of this clinical trial is to learn if radical surgery improves prognosis and quality of life compared with continued standard non-surgical treatment in gastric cancer patients with peritoneal metastasis who have achieved successful conversion therapy. The main questions it aims to answer are:
- Does radical surgery prolong overall survival in patients who achieve successful conversion therapy?
- Does radical surgery provide better or at least comparable quality of life and safety outcomes compared with continued standard treatment? Researchers will compare radical surgery versus continued standard systemic treatment to see whether radical surgery provides superior clinical benefit for patients after successful conversion therapy.
Participants will:
- Initial laparoscopic exploration confirms CY0P1 or CY1P1, absence of distant organ metastasis, a PCI ≤ 20, and presence or absence of ascites.
- Receive conversion therapy (chemotherapy, targeted/immunotherapy, intraperitoneal therapy, etc.) per standard guidelines, tailored to the patient's condition and molecular-pathological profile
- If clinical conversion is confirmed, undergo a second laparoscopic exploration to verify successful conversion
- If successful conversion is confirmed (peritoneal lesions cleared or markedly regressed with negative biopsy, no ascites or distant metastases, R0-resectable primary tumor, and improved patient condition), be randomized 1:1 to either the surgery group or the standard treatment group
- In the surgery group, undergo curative gastrectomy with D2 lymphadenectomy during the second laparoscopy, followed by adjuvant therapy and maintenance treatment
- In the standard treatment group, continue systemic therapy without surgery, with maintenance treatment and salvage surgery permitted if clinically indicated
- Complete quality of life questionnaires at predefined time points
- Be followed up for survival, disease progression, adverse events and medical resource use outcomes
Studie Overzicht
Toestand
Nog niet aan het werven
Conditie
Studietype
Ingrijpend
Inschrijving (Geschat)
170
Fase
- Fase 3
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studiecontact
- Naam: Hua Huang
- Telefoonnummer: +86-13816151816
- E-mail: huahuang@fudan.edu.cn
Studie Locaties
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100853
- Chinese PLA General Hospital
-
Contact:
- xiaohui du
- Telefoonnummer: +86 010-68182255
- E-mail: duxiaohui301@sina.com
-
Beijing, Beijing Municipality, China, 102206
- Peking University International Hospital
-
Contact:
- ning ning
- Telefoonnummer: +86 010-69006666
- E-mail: ningning301@126.com
-
Beijing, Beijing Municipality, China, 100142
- Peking University Cancer Hospital
-
Contact:
- ziyu li
- Telefoonnummer: +86 010-88121122
- E-mail: ziyu_li@hsc.pku.edu.cn
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, China, 400038
- The First Affiliated Hospital of Army Medical University
-
Contact:
- yan shi
- Telefoonnummer: +86 023-68765109
- E-mail: shiyanpwk@tmmu.edu.cn
-
-
Fujian
-
Zhangzhou, Fujian, China, 363000
- Zhangzhou Affiliated hospital of Fujian Medical University
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- Sun Yat-sen University Cancer Center
-
Contact:
- huiyan luo
- Telefoonnummer: +86 020-87343571
- E-mail: luohy@sysucc.org.cn
-
Guangzhou, Guangdong, China, 510515
- Nanfang Hospital, Southern Medical University
-
Contact:
- yanfeng hu
- Telefoonnummer: +86 020-61641888
- E-mail: banby@smu.edu.cn
-
Guangzhou, Guangdong, China, 510655
- The Sixth Affiliated Hospital, Sun Yat-sen University
-
Contact:
- shi chen
- Telefoonnummer: +86 020-38254000
- E-mail: chensh47@mail.sysu.edu.cn
-
-
Hubei
-
Wuhan, Hubei, China, 430030
- Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
-
Contact:
- guihua wang
- Telefoonnummer: +86 027-83665555
- E-mail: ghwang@tjh.tjmu.edu.cn
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210029
- Jiangsu Province Hospital
-
Contact:
- hao xu
- Telefoonnummer: +86 025-83718836
- E-mail: hxu@njmu.edu.cn
-
Nanjing, Jiangsu, China, 210009
- Jiangsu Cancer Hospital
-
Contact:
- chao yue
- Telefoonnummer: +86 025-83283597
- E-mail: yuechaomeng@126.com
-
Nanjing, Jiangsu, China, 210008
- Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medicine School
-
Contact:
- jia wei
- Telefoonnummer: +86 025-83106666
- E-mail: jiawei99@nju.edu.cn
-
Nantong, Jiangsu, China, 226001
- Nantong First People's Hospital
-
Contact:
- shichun feng
- Telefoonnummer: +86 0513-81111888
- E-mail: fsc2200@126.com
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330006
- The First Affiliated Hospital of Nanchang University
-
Contact:
- zhengrong li
- Telefoonnummer: +86 0791-88692748
- E-mail: lzr13@foxmail.com
-
Nanchang, Jiangxi, China, 330006
- The Second Affiliated Hospital of Nanchang University
-
Contact:
- bin lai
- Telefoonnummer: +86 0791-86120120
- E-mail: Vincent83126@163.com
-
Shangrao, Jiangxi, China, 334000
- Shangrao People's Hospital
-
Contact:
- jinqiang chen
- Telefoonnummer: +86 0793-8100469
- E-mail: CJQ760624@126.com
-
-
Jilin
-
Changchun, Jilin, China, 130021
- The First Hospital of Jilin University
-
Contact:
- quan wang
- Telefoonnummer: +86 0431-88782222
- E-mail: wquan@jlu.edu.cn
-
-
Liaoning
-
Dalian, Liaoning, China, 116011
- The First Affiliated Hospital of Dalian Medical University
-
Contact:
- pin liang
- Telefoonnummer: +86 0411-83635963
- E-mail: sunnyliangpin@163.com
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710061
- The First Affiliated Hospital of Xi'an Jiaotong University
-
Contact:
- peng xia
- Telefoonnummer: +86 029-85323200
- E-mail: peng_xia666@126.com
-
Xi'an, Shaanxi, China, 710038
- The Second Affiliated Hospital of Airforce Military Medical University
-
Contact:
- nan wang
- Telefoonnummer: +86 029-84777777
- E-mail: wangnandoc@fmmu.edu.cn
-
-
Shandong
-
Jinan, Shandong, China, 250021
- Shandong Provincial Hospital
-
Contact:
- changqing jing
- Telefoonnummer: +86 0531-87938911
- E-mail: jingchangqing@sdfmu.edu.cn
-
Jinan, Shandong, China, 250014
- The First Affiliated Hospital of Shandong First Medical University
-
Contact:
- jiankang zhu
- Telefoonnummer: +86 0531-89268763
- E-mail: 249217523@qq.com
-
Qingdao, Shandong, China
- The Affiliated Hospital of Qingdao University
-
Contact:
- zhaojian niu
- Telefoonnummer: +86 0532-82911847
- E-mail: niuzhj@hotmail.com
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200032
- Fudan University Shanghai Cancer Center
-
Contact:
- Hua Huang, MD, PhD
- Telefoonnummer: +86-13816151816
- E-mail: huahuang@fudan.edu.cn
-
Hoofdonderzoeker:
- Hua Huang, MD,PHD
-
Shanghai, Shanghai Municipality, China
- Shanghai General Hospital
-
Contact:
- yuan fang
- Telefoonnummer: +86 021-63240090
- E-mail: Fangyuan1231@aliyun.com
-
-
Shanxi
-
Changzhi, Shanxi, China, 046000
- Changzhi People'S Hospital
-
Contact:
- liang zong
- Telefoonnummer: +86 0355-2024990
- E-mail: 250537471@qq.com
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, China, 300060
- Tianjin Medical University Cancer Institute&Hospital
-
Contact:
- xiangyang yu
- Telefoonnummer: +86 022-23109106
- E-mail: yxynankai@126.com
-
-
Xinjiang
-
Ürümqi, Xinjiang, China, 830011
- Affiliated Cancer Hospital of Xinjiang Medical University
-
Contact:
- wenbin zhang
- Telefoonnummer: +86 0991-7968088
- E-mail: zwb3216@sina.com
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310022
- Zhejiang Cancer Hospital
-
Contact:
- panpan yu
- Telefoonnummer: +86 0571-88122222
- E-mail: yupp0571@163.com
-
Hangzhou, Zhejiang, China, 310009
- The Second Affiliated Hospital Zhejiang University School of Medicine
-
Contact:
- jiaqi chen
- Telefoonnummer: +86 0571-87783777
- E-mail: 2311046@zju.edu.cn
-
Hangzhou, Zhejiang, China, 310016
- Sir Run Run Shaw Hospital, affiliated with Zhejiang University School of Medicine
-
Contact:
- linghua zhu
- Telefoonnummer: +86 0571-86090073
- E-mail: 3198020@zju.edu.cn
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Nee
Beschrijving
Inclusion Criteria:
- Patients voluntarily participate in the study, sign the informed consent form, and demonstrate good compliance.
- Age ≥ 18 years and ≤ 70 years.
- Histologically and/or cytologically confirmed gastric cancer.
- No evidence of gastric outlet obstruction or intestinal obstruction.
- No distant metastasis on imaging examination. Initial laparoscopic exploration confirms CY0P1 or CY1P1, without distant organ metastasis, with a recorded peritoneal carcinomatosis index (PCI) ≤ 20, and with either positive or negative ascites. Patients meeting these criteria are eligible for pre-enrollment. Following successful conversion therapy, a second laparoscopic exploration must confirm conversion to CY0P0, with no distant organ metastases and no regional lymph node metastases beyond the second station. Only upon meeting these criteria are patients formally enrolled in the study.
- No prior chemotherapy, targeted therapy, or immunotherapy.
- ECOG performance status score of 0-2.
- Life expectancy ≥ 12 weeks.
- Laboratory requirements: Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L, platelet count ≥ 75 × 10⁹/L, hemoglobin ≥ 8 g/dL; Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × upper limit of normal (ULN); total bilirubin ≤ 1.5 × ULN. In the presence of liver metastases, AST and ALT ≤ 5 × ULN; Serum creatinine (Cr) ≤ 1.5 × ULN, or creatinine clearance (CCr) ≥ 60 mL/min; International normalized ratio (INR) ≤ 1.5 × ULN; prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.
Exclusion Criteria:
- Initial laparoscopic exploration reveals P0, or either of the two laparoscopic explorations reveals distant organ metastasis or distant lymph node metastasis.
- Prior anticancer therapy, including chemotherapy, targeted therapy, or immunotherapy.
- Hypertension that cannot be adequately controlled with antihypertensive medication (systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg).
- Active bleeding or coagulation disorder within 2 months prior to enrollment, bleeding tendency, or ongoing thrombolytic therapy, deemed by the investigator as unsuitable for enrollment.
- Active cardiac disease within 6 months prior to treatment, including myocardial infarction, severe/unstable angina pectoris. Left ventricular ejection fraction (LVEF) < 50% on echocardiography, or poorly controlled arrhythmia.
- Known allergy to immunotherapy agents, chemotherapy agents, or any of their excipients.
- Pregnancy (positive pregnancy test prior to treatment initiation) or breastfeeding.
- Active or uncontrolled severe infection: Severe infection within 4 weeks prior to enrollment (e.g., requiring intravenous antibiotics, antifungals, or antivirals); Known human immunodeficiency virus (HIV) infection; History of clinically significant liver disease, including viral hepatitis. For known hepatitis B virus (HBV) carriers, active HBV infection must be excluded, defined as HBV DNA positive (> 1 × 10⁴ copies/mL or > 2000 IU/mL); Known hepatitis C virus (HCV) infection with positive HCV RNA (> 1 × 10³ copies/mL), or other hepatitis, cirrhosis.
- Urinalysis indicating proteinuria ≥ 2+, with 24-hour urine protein quantification > 1.0 g.
- Any other condition deemed by the investigator as inappropriate for participation in this study.
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Surgery Group
|
Patients undergo curative gastrectomy with D2 lymphadenectomy (laparoscopic, robotic, or open) during second-look laparoscopy after successful conversion therapy.
Postoperatively, they receive adjuvant systemic therapy (continuing the preoperative regimen or MDT-modified protocol) for up to 8 cycles total, followed by maintenance therapy for up to 1 year after randomization, or until disease progression, unacceptable toxicity, or withdrawal.
|
|
Actieve vergelijker: Standard Treatment Group
|
Patients do not undergo surgery.
They continue the original conversion regimen or an MDT-adjusted systemic therapy for a total of 8 cycles, followed by maintenance therapy for up to 1 year after randomization, or until disease progression, unacceptable toxicity, or withdrawal.
Salvage surgery is permitted if clinically indicated.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Overall Survival (OS)
Tijdsspanne: Up to 3 years after randomization
|
Up to 3 years after randomization
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Quality of Life (QoL) assessed by EORTC QLQ-C30 questionnaires
Tijdsspanne: Prior to first-look laparoscopy, prior to second-look laparoscopy, 1-month post-randomization, 3-months post-randomization, then every 3-months thereafter up to 3-years after randomization
|
Prior to first-look laparoscopy, prior to second-look laparoscopy, 1-month post-randomization, 3-months post-randomization, then every 3-months thereafter up to 3-years after randomization
|
|
|
Quality of Life (QoL) assessed by EORTC QLQ-STO22 questionnaires
Tijdsspanne: Prior to first-look laparoscopy, prior to second-look laparoscopy, 1-month post-randomization, 3-months post-randomization, then every 3-months thereafter up to 3-years after randomization
|
Prior to first-look laparoscopy, prior to second-look laparoscopy, 1-month post-randomization, 3-months post-randomization, then every 3-months thereafter up to 3-years after randomization
|
|
|
Pathological Complete Response (pCR) Rate
Tijdsspanne: At the time of radical surgery
|
At the time of radical surgery
|
|
|
R0 Resection Rate
Tijdsspanne: At the time of radical surgery
|
At the time of radical surgery
|
|
|
Complication-Free Survival
Tijdsspanne: Up to 3 years after randomization
|
Up to 3 years after randomization
|
|
|
Major Complication Rate
Tijdsspanne: Within 30 days and 90 days after surgery
|
Within 30 days and 90 days after surgery
|
|
|
Progression-Free Survival (PFS) and Peritoneal PFS
Tijdsspanne: Up to 3 years after randomization
|
Up to 3 years after randomization
|
|
|
Time to Peritoneal Re-dissemination
Tijdsspanne: Up to 3 years after randomization
|
Up to 3 years after randomization
|
|
|
Length of Hospital Stay
Tijdsspanne: Perioperative period
|
Duration of postoperative hospital stay, calculated from the date of surgical intervention to the date of hospital discharge, only applicable to participants receiving surgical treatment.
|
Perioperative period
|
|
Readmission Rate
Tijdsspanne: Within 30 days and 90 days post-surgery
|
Within 30 days and 90 days post-surgery
|
|
|
Treatment Interruption Rate
Tijdsspanne: Within 1-year after randomization
|
Within 1-year after randomization
|
|
|
Direct Medical Costs / Hospitalization Costs
Tijdsspanne: Baseline through study completion, an average of 3-years post-randomization
|
Direct medical costs are defined as all medical expenses directly related to the patient's care, including hospitalization, surgery, medications, laboratory tests, imaging examinations, and management of complications.
Data will be collected continuously throughout the study period (from baseline until death or study completion) and aggregated at the end of the study.
|
Baseline through study completion, an average of 3-years post-randomization
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Geschat)
1 oktober 2026
Primaire voltooiing (Geschat)
1 oktober 2031
Studie voltooiing (Geschat)
1 oktober 2031
Studieregistratiedata
Eerst ingediend
23 augustus 2026
Eerst ingediend dat voldeed aan de QC-criteria
26 augustus 2026
Eerst geplaatst (Werkelijk)
27 augustus 2026
Updates van studierecords
Laatste update geplaatst (Werkelijk)
27 augustus 2026
Laatste update ingediend die voldeed aan QC-criteria
26 augustus 2026
Laatst geverifieerd
1 augustus 2026
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 2606346-6-2608A
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
NEE
Beschrijving IPD-plan
Individual-participant-level raw data will not be shared externally.
Aggregated study results will be published in peer-reviewed journals.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Nee
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .